Alain Horvais is a Partner at Kurma Partners who specifically leads their diagnostics fund, bringing a decade of hands-on experience from senior roles at Bio-Rad and AstraZeneca where he built and industrialized complex diagnostic tools. He combines a PhD in molecular biology with formal training in biotechnology management and is recognized as a panel expert on the risks and limits of developing complex biomarkers into scalable diagnostic products.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































